Back to Directory
Last Updated: 08/06/2026
Isoform Oncology
Stevenage
Founded 2024
Cancer biotherapeutics targeting disease-specific protein isoforms
Isoform Oncology is an early-stage biotechnology company developing cancer therapeutics based on isoform switching and alternative RNA splicing.
The company identifies cancer-specific protein variants arising from aberrant splicing and develops biotherapeutics designed to selectively target these disease-specific isoforms, with a focus on precision oncology in treatment-resistant settings.
Based at Stevenage Bioscience Catalyst and backed by Zinc Ventures, the company was founded in 2024.